Head-to-head · Cost-Efficiency Index
Maves vs Amble
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Maves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesAmble
Cost-first shoppers who want a single flat rate across semaglutide and tirzepatide, if a 12-month prepay is acceptable.
Visit AmbleThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 74. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. Amble still earns a C — Cost-first shoppers who want a single flat rate across semaglutide and tirzepatide, if a 12-month prepay is acceptable.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Maves | Amble |
|---|---|---|
| Cost-Efficiency Index | 76/100 | 74/100 |
| Semaglutide / mo | $89/mo (starting dose, compounded) | $179/mo (all doses, compounded) |
| Tirzepatide / mo | Not disclosed | $179/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $1,068 | $2,148 |
| Tirzepatide / yr (modeled) | — | $2,148 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #49 | #56 |
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Amble
74/100Where the value is
- No difference in price between semaglutide and tirzepatide — genuinely one pricing table for both
- True no-commitment option exists ($179/mo, pay as you go) alongside the prepay tiers
- All 50 states, with only 5 requiring a live video visit instead of async intake
The tradeoffs
- The advertised low-end price ($135-$160/mo) is not a monthly bill — it's a one-time lump-sum prepay for the whole 3/6/12-month term, stated explicitly on the page
- No named medical director, prescriber, or compounding pharmacy anywhere on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.